Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 926,719
  • Shares Outstanding, K 74,555
  • Annual Sales, $ 851,100 K
  • Annual Income, $ 4,600 K
  • 60-Month Beta 1.29
  • Price/Sales 1.21
  • Price/Cash Flow 5.27
  • Price/Book 0.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.49
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.68
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -263.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.10 +15.95%
on 07/14/20
13.02 -1.15%
on 08/12/20
+1.40 (+12.21%)
since 07/10/20
3-Month
10.54 +22.11%
on 06/25/20
16.92 -23.94%
on 06/05/20
-1.50 (-10.44%)
since 05/12/20
52-Week
9.24 +39.29%
on 03/18/20
47.10 -72.68%
on 08/13/19
-32.41 (-71.58%)
since 08/12/19

Most Recent Stories

More News
The global market for next generation breast cancer diagnostics and screening market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030

, /PRNewswire/ --

ABT : 100.99 (+1.95%)
A : 97.89 (+1.65%)
BIOC : 1.0250 (+2.50%)
FLGT : 40.82 (-0.22%)
NVTA : 29.92 (+3.14%)
MYGN : 12.99 (+4.51%)
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a new study published in the peer-reviewed journal Genetics in Medicine demonstrates the...

MYGN : 12.99 (+4.51%)
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors...

MYGN : 12.99 (+4.51%)
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MYGN : 12.99 (+4.51%)
Medicare Expands Coverage for BRACAnalysis(R) CDx in Prostate Cancer

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis CDx for men with prostate cancer who...

MYGN : 12.99 (+4.51%)
Expected Growth in Cancer Cases Reinforces Need for Superior Diagnostic Options

, /PRNewswire/ --The cancer diagnostics market is highly competitive, with a large number of big and small players operating in various market segments. Technological advancements in various fields such...

ANPC : 6.70 (-9.09%)
EXAS : 87.95 (+5.10%)
NEO : 39.79 (+1.43%)
VCYT : 33.34 (+2.30%)
MYGN : 12.99 (+4.51%)
Myriad Launches Proprietary AMPLIFY(TM) Technology, Further Increasing the Performance of its Prequel(TM) NIPS Test

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY(TM) technology, which further increases...

MYGN : 12.99 (+4.51%)
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra(R)

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra test...

MYGN : 12.99 (+4.51%)
Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad's Board of Directors. Walter (Wally)

MYGN : 12.99 (+4.51%)
New Study Demonstrates the Ability of myPath(R) Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that a new study published in Future Medicine demonstrates the ability of myPath Melanoma...

MYGN : 12.99 (+4.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MYGN with:

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 13.08
1st Resistance Point 12.76
Last Price 12.99
1st Support Level 12.15
2nd Support Level 11.86

See More

52-Week High 47.10
Fibonacci 61.8% 32.64
Fibonacci 50% 28.17
Fibonacci 38.2% 23.70
Last Price 12.99
52-Week Low 9.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar